GSK3B and glioblastoma: Together, these findings have demonstrated that the difference in GSK3β-mediated NHEJ regulation between healthy neural tissue and glioma cells can be exploited to benefit the patient, and have provided strong preclinical evidence and rational for clinical implementation of GSK3β inhibition in combination with standard GBM treatment (Figure 2).